Related Experiment Videos
Oral contraceptives and venous thromboembolism. A case-control study
O Lidegaard1, B Edström, S Kreiner
1Department of Obstetrics and Gynecology, Herlev Hospital, University of Copenhagen, Denmark. Lidegaard@dadlnet.dk
Contraception
|July 23, 1998
Summary
Oral contraceptives (OC) significantly increase the risk of venous thromboembolism (VTE) in young women. The risk is primarily linked to the duration of OC use, not estrogen dose or progestin type.
Area of Science:
- Reproductive Health
- Cardiovascular Thrombosis
- Pharmacovigilance
Background:
- Venous thromboembolism (VTE) is a significant health concern in young women.
- Oral contraceptives (OC) are widely used for contraception and hormonal therapy.
- Assessing the VTE risk associated with OC use is crucial for patient safety.
Purpose of the Study:
- To evaluate the association between oral contraceptive use and the risk of venous thromboembolism (VTE) in women aged 15-44.
- To determine if estrogen dose or progestin type influences VTE risk in OC users.
- To investigate the impact of OC duration of use on VTE risk.
Main Methods:
- A 5-year case-control study conducted in Danish hospitals (1994-1995).
- Included women aged 15-44 experiencing a first deep venous thrombosis or pulmonary embolism (cases) and matched controls.
- Multivariate analysis adjusted for confounders like BMI, smoking, and family history.
Main Results:
- Oral contraceptive use significantly increases VTE risk.
- VTE risk was highest with less than 1 year of OC use (OR 5.1) and decreased with longer duration.
- No significant influence of estrogen dose or progestin generation on VTE risk after adjusting for duration of use.
Conclusions:
- Oral contraceptives are associated with a significantly elevated risk of VTE.
- The duration of oral contraceptive use is the primary determinant of VTE risk.
- Healthcare providers should consider duration of use when prescribing oral contraceptives to mitigate VTE risk.